Ignite Creation Date:
2025-12-25 @ 2:50 AM
Ignite Modification Date:
2025-12-31 @ 4:55 PM
Study NCT ID:
NCT00811733
Status:
COMPLETED
Last Update Posted:
2017-05-30
First Post:
2008-12-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of ofatumumab is being initiated in patients with Waldenstrom's Macroglobulinemia (WM).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: